Good cop bad cop. Drug will not be approved but she can say I tried.
A study with 12 kids proves little. Shorts sniffed out the ruse.
They should have waited until full study was done.
company and done a large study. Keeping the study to 12 kids was foolish.
do a proper study of its drug.
morning. Another bad sign.
only 12 kids? At best I would assume the FDA will want to see the completion of the bigger study.
AHTPRE has a higher interest rate. What is going on?
Anyone know. Move up right after going ex -dividend is not the norm.
anticipated. GILD will appeal anyways. Merck will end up with little or no payments. GILD will be back to $100 soon.
Court case? Merger? Stock just too cheap? Up on ex-dividend day is unusual
"never" is a word I would never use when assessing risk. In Bk a lease can be renegotiated.
down. Seems like NRF is fixing the leaky boat.
Paying over 11% and now more secure given improved finances.
Only one question when will you cover $100, $105 or $110.
Harvoni has real world safety data from patients. We will see about Zepatier
dividend so it can manage any cut in payments from BK's of companies
I am now getting back into gold stocks. RIC is profitable and safe.
Walgreen if they do not get financing?